Moderna, Inc.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the Uni…
Biotechnology
US, Cambridge [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -73.40 | -32.12 | 120.75 | |
| Graham Fair Price | 123.23 | 48.19 | 21.59 | |
| PEG | -96.75 | 0.01 | -0.41 | |
| Price/Book | 15.08 | 3.15 | 2.73 | |
| Price/Cash Flow | -63.88 | -34.04 | 94.25 | |
| Prices/Earnings | -80.34 | -8.58 | 43.65 | |
| Price/Sales | 1693.29 | 241.55 | 13.47 | |
| Price/FCF | -63.88 | -34.04 | 94.25 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -68.71 | 0.21 | 0.67 | |
| Operating Margin | 355314.97 | -7.58 | < 0.005 | |
| ROA | 496.40 | -0.07 | 0.01 | |
| ROE | 0.02 | -0.09 | 485.28 | |
| ROIC | < 0.005 | -0.09 | 7274.34 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | < 0.005 | -0.02 | 78.83 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 1.00 | -212.00 | 21036.97 | |
| EPS QOQ | 1.06 | -6.40 | 504.21 | |
| FCF QOQ | 1.23 | -3.95 | 220.69 | |
| Revenue QOQ | 0.54 | -0.94 | 75.39 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Positive
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 19.57 | 201.14 | 927.81 | |
| Days Sales Outstanding (DSO) | 34.59 | 208.56 | 503.03 | |
| Inventory Turnover | 4.60 | 0.45 | -90.27 | |
| Debt/Capitalization | 0.08 | 0.09 | 6.90 | |
| Quick Ratio | 3.21 | 3.75 | 16.77 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 36.36 | 33.55 | -7.73 | |
| Cash | 22.58 | 22.36 | -1.00 | |
| Capex | -0.58 | -0.51 | 11.14 | |
| Free Cash Flow | 1.06 | -3.10 | 194.00 | |
| Revenue | 7.38 | 0.44 | -94.08 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad